This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Khorana AA et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119:648–655.KhoranaAAIncidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States201311964865510.1002/cncr.2777222893596Search in Google Scholar
Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32: S3–S7KesslerCMThe link between cancer and venous thromboembolism: a review200932S3S710.1097/COC.0b013e3181b01b1719654481Search in Google Scholar
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160:809–815.HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJ3rdRisk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study200016080981510.1001/archinte.160.6.80910737280Search in Google Scholar
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293:715–722.BlomJWDoggenCJOsantoSRosendaalFRMalignancies, prothrombotic mutations, and the risk of venous thrombosis200529371572210.1001/jama.293.6.71515701913Search in Google Scholar
Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22:vi85–vi92MandalàMFalangaARoilaFESMO Guidelines Working GroupManagement of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines201122vi85vi9210.1093/annonc/mdr39221908511Search in Google Scholar
ASCO 2015 Guidelines/VTE. Available at http://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/VTE-Summary-of-Recs.pdfAvailable at http://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/VTE-Summary-of-Recs.pdfSearch in Google Scholar
National Institute for Health and Care Excellence (2018) Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline (NG89). Available at https://www.nice.org.uk/guidance/ng89. Last accessed December 2018National Institute for Health and Care Excellence2018NICE guideline (NG89). Available at https://www.nice.org.uk/guidance/ng89. Last accessed December 2018Search in Google Scholar
van Es N, CoppensM, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968–1975van EsNCoppensMSchulmanSMiddeldorpSBüllerHRDirect oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials2014124121968197510.1182/blood-2014-04-57123224963045Search in Google Scholar
Khorana AA. et al Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720–728KhoranaAARivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer201938072072810.1056/NEJMoa181463030786186Search in Google Scholar
Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012; 10:807–14.LevineMNGuCLiebmanHAEscalanteCPSolymossSDeitchmanDA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer2012108071410.1111/j.1538-7836.2012.04693.x22409262Search in Google Scholar
Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S et al. Apixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019;94(6):635–640PegourieBKarlinLBenboubkerLOrsini-PiocelleFTiabMAuger-QuittetSApixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study201994663564010.1002/ajh.2545930859608Search in Google Scholar
Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9:653–63.CarrierMLe GalGTayJWuCLeeAYRates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis201196536310.1111/j.1538-7836.2011.04215.x21255254Search in Google Scholar
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.GoldhaberSZLeizoroviczAKakkarAKHaasSKMerliGKnabbRMADOPT Trial InvestigatorsApixaban versus enoxaparin for thromboprophylaxis in medically ill patients201136521677710.1056/NEJMoa111089922077144Search in Google Scholar
Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D et al. Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy, a 3-Month Interim Analysis. ASH 2018. https://ash.confex.com/ash/2018/webprogram/Paper112577.html (accessed January 14, 2019).CornellRFGoldhaberSZEngelhardtBGMoslehiJJagasiaMPattonDASH 2018. https://ash.confex.com/ash/2018/webprogram/Paper112577.html (accessed January 14, 2019).Search in Google Scholar
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 21; 380:711–719CarrierMAbou-NassarKMallickRTagalakisVShivakumarSSchattnerAApixaban to Prevent Venous Thromboembolism in Patients with Cancer20192138071171910.1056/NEJMoa181446830511879Search in Google Scholar
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med.2018 15; 378:615–624.RaskobGEvan EsNVerhammePCarrierMDi NisioMGarciaDEdoxaban for the Treatment of Cancer-Associated Venous Thromboembolism20181537861562410.1056/NEJMoa171194829231094Search in Google Scholar
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al. Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 10; 36:2017–2023.YoungAMMarshallAThirlwallJChapmanOLokareAHillCComparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)201810362017202310.1200/JCO.2018.78.803429746227Search in Google Scholar
McBane II R, Loprinzi CL, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A. et al. Apixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism. The ADAM VTE Trial. J Thromb Haemost. 2019. [Epub ahead of print]McBaneRIILoprinziCLLe-RademacherJGZemlaTAshraniATafurAApixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism. The ADAM VTE Trial2019[Epub ahead of print]10.1111/jth.1466231630479Search in Google Scholar
Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019; 380(8):781–783AgnelliGDirect Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer2019380878178310.1056/NEJMe181606030786193Search in Google Scholar
Brunetti ND, Tricarico L, Correale M, De Gennaro L, Santoro F, Ieva R et al. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials. J Thromb Thrombolysis. 2019. [Epub ahead of print]BrunettiNDTricaricoLCorrealeMDe GennaroLSantoroFIevaRDirect oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials2019[Epub ahead of print]10.1007/s11239-019-01974-y31654194Search in Google Scholar